As the regenerative medicine and high-end cosmetic sectors pivot away from animal-derived proteins, CD BioGlyco stands at the forefront of bioengineering with our recombinant type I human collagen production service. Type I collagen is the primary structural protein in the human extracellular matrix, responsible for skin elasticity, tissue tensile strength, and wound healing. Traditionally, collagen was extracted from bovine or porcine tissues, posing risks of zoonotic disease transmission and immunogenic reactions. CD BioGlyco utilizes advanced eukaryotic and plant-based expression systems to synthesize "human-identical" collagen. Our recombinant technology ensures a high-purity, biocompatible product with a defined triple-helical structure, specifically engineered to provide superior bioactive signals to fibroblasts. By eliminating the batch-to-batch variability of animal extraction, we empower brands to deliver predictable results in every formulation.
Core Technologies
We leverage a proprietary technology stack to overcome the historical challenges of recombinant collagen stability and hydroxylation:
Dual-Vector Eukaryotic Expression
We utilize optimized Chinese Hamster Ovary (CHO) and Pichia pastoris systems that co-express human prolyl 4-hydroxylase (P4H), ensuring the essential post-translational modifications required for thermal stability.
Tobacco Plant Molecular Farming
For large-scale, sustainable production, we deploy a plant-based platform where human collagen genes are expressed alongside modifying enzymes, yielding a "green" collagen with high bioactivity.
Intelligent Codon Optimization
Our bioinformatics pipeline redesigns human collagen gene sequences to match the tRNA abundance of the host organism, significantly increasing protein titer and folding precision.
Triple-Helix Stability Engineering
We employ structural biology insights to ensure that the recombinant chains assemble into stable homotrimers, mimicking the natural architecture of human dermal collagen.
High-Resolution Chromatography Purification
A multi-step downstream process utilizing ion-exchange and size-exclusion chromatography to achieve 99% purity, removing all host cell proteins (HCP) and DNA.
Defining the Future of Bio-Identical Regeneration.
The service scope is engineered to support the most demanding requirements of the global cosmeceutical and biomedical industries. We provide a comprehensive development pipeline, which includes the design of specific collagen fragments or full-length molecules depending on the desired bioactivity. Our service covers the production of sterile lyophilized powder, designed for direct integration into premium anti-aging serums, injectable fillers, and wound care scaffolds. We offer tailored hydroxylation profiles, allowing clients to specify the degree of proline modification to fine-tune the thermal stability of the collagen for different climate regions or application types.
CD BioGlyco also provides custom formulation consulting, where our scientists assist in developing stable emulsions or gels that preserve the collagen's triple-helical structure during shelf life. We specialize in plant-based and fermentation-based options, giving brands the flexibility to choose a production pathway that aligns with their sustainability or "vegan" marketing goals. Whether you are developing a revolutionary post-laser recovery cream or a high-performance firming lotion, CD BioGlyco provides the structural backbone of your innovation, ensuring a reliable, high-titer supply of the world's most critical structural protein.
Workflow
Gene Synthesis & Host Transformation
We design and synthesize optimized, humanized collagen gene sequences tailored for high-yield expression. This includes constructing specialized co-expression vectors carrying genes for essential modifying enzymes, such as prolyl hydroxylase. These constructs are then precisely transformed into our proprietary high-performance expression chassis, which includes optimized microbial systems or plant-based platforms, to ensure efficient transcription and translation.
Small-Scale Expression Screening
Transformed clones undergo high-throughput screening in automated micro-bioreactor arrays. We rapidly assess hundreds of lines in parallel, measuring key metrics including total protein yield, prolyl hydroxylation efficiency (via mass spectrometry), and correct triple-helical structure formation (via circular dichroism). This identifies elite production clones with the ideal balance of productivity and structural fidelity for scale-up.
Fermentation & Scale-Up
The lead production clone is transferred to controlled industrial-scale bioreactors. Here, critical parameters, including dissolved oxygen, pH, temperature, and nutrient feed, are continuously monitored and tightly controlled. This maintains the precise physiological conditions required to support proper protein folding, post-translational modification, and the assembly of stable collagen triple helices at scale.
Enzymatic Processing & Extraction
Following fermentation, procollagen is harvested and purified from the culture broth. It is then treated with specific, recombinant peptidases in a controlled enzymatic cleavage step. This process precisely removes the N- and C-terminal pro-peptides, converting the precursor into mature, biologically active type I collagen monomers ready for further purification and fibrillogenesis.
Polished Purification
The mature collagen undergoes multi-step chromatography using automated systems, such as affinity, ion-exchange, and size-exclusion columns. This rigorous process separates and isolates the pure collagen homotrimers from host cell proteins, nucleic acids, endotoxins, and other process-related impurities, resulting in a sterile, pyrogen-free intermediate of pharmaceutical-grade purity.
Lyophilization & Analytical Characterization
The purified collagen solution is aseptically filled and lyophilized into a stable, white powder. The final product is subjected to a comprehensive suite of analytical tests. This includes circular dichroism (CD) spectroscopy to confirm the characteristic triple-helical secondary structure and differential scanning calorimetry (DSC) to measure its thermal denaturation temperature (Tm), thereby verifying the protein's stability and conformational integrity prior to release.
Publication Data
Journal: Life
DOI: 10.3390/life15040582
Published: 2025
IF: 3.4
Results: This article is a comprehensive review that systematically examines the clinical advancements and applications of recombinant human collagen (RHC). The authors, through an analysis of relevant studies and clinical trials, detail how RHC, produced via recombinant DNA technology, overcomes the limitations of animal-derived collagen, such as immunogenicity and zoonotic risk. The review highlights RHC's superior mechanical properties and controlled degradation, demonstrating its proven efficacy in accelerating wound healing, promoting dermal regeneration, and supporting tissue engineering in areas like skin, bone, and cardiovascular repair. It also covers its emerging roles in drug delivery, gynecology, and oncology. The authors conclude that while RHC represents a transformative and safer biomaterial for improving patient outcomes, challenges like high production costs and regulatory hurdles remain barriers to its widespread clinical adoption.
Applications
Premium Anti-Aging Serums
Incorporating full-length recombinant type I collagen to provide an immediate firming effect while simultaneously signaling the skin to increase its own structural protein synthesis for long-term rejuvenation.
Regenerative Post-Laser Creams
Utilizing the high biocompatibility of human-identical collagen to soothe skin and accelerate re-epithelialization following intensive dermatological procedures like CO2 laser resurfacing or deep chemical peels.
Bio-Scaffolds for Wound Healing
Developing advanced dressings that use recombinant collagen to provide a structural matrix for cell migration, significantly improving the healing rate of chronic wounds and surgical incisions.
Injectable Dermal Fillers
Producing high-purity, non-immunogenic collagen for the next generation of soft-tissue fillers that offer a natural feel and superior biological integration compared to synthetic or animal-based alternatives.
Advantages
Absolute Human Identity
Our recombinant collagen is genetically identical to human type I collagen, ensuring 100% biocompatibility. Unlike animal-sourced versions, our collagen provides the exact ligand-binding sites required to stimulate endogenous collagen production in human skin cells.
Superior Thermal Stability
Utilizing co-expressed P4H enzymes, our collagen achieves high levels of hydroxylation, allowing the triple helix to remain stable at body temperature (37°C), which is critical for long-term efficacy in topical and injectable products.
Minimal Immunogenicity
Because the protein sequence is human-identical and purified to >99%, it avoids the inflammatory responses often triggered by foreign animal proteins, making it suitable for even the most sensitive or compromised skin types.
Highly Consistent Molecular Weight
Our biosynthetic platform produces collagen with a defined molecular weight and sequence, eliminating the batch-to-batch variability found in natural extraction, which leads to more predictable formulation performance and clinical outcomes.
Frequently Asked Questions
Customer Review
"The thermal stability of CD BioGlyco collagen is the best we've seen. It integrated perfectly into our new anti-aging line without requiring complex stabilization additives."
– Manager, Formulation Lab
"We conducted a comparative study and found that the cell adhesion rates with CD BioGlyco's human-sequence collagen were 30% higher than with bovine alternatives."
– Dr. J.W., Director of Dermatology Research
"Switching to a biosynthetic source allowed us to meet our company's sustainability goals while actually improving the performance of our premium serums."
– Senior VP of Product Development
Associated Services
To optimize your production efficiency and product performance, we offer several complementary services:
Production of critical prebiotic trisaccharides for microbiome-balancing formulations.
CD BioGlyco is dedicated to pioneering the future of biomaterials by providing the world's most advanced bio-identical structural proteins. Our flagship recombinant type I human collagen, produced via a precision fermentation platform, sets the definitive standard for brands that demand uncompromising safety, superior biocompatibility, and proven bioactivity. It is a sustainable, scientifically superior alternative to animal-derived sources, being animal-free, pathogen-free, and batch-to-batch consistent. Contact us today to integrate this transformative ingredient into your next-generation skincare, medical, and wellness products.
Reference
Jie, I.W.K.; et al. Advancements in clinical utilization of recombinant human collagen: an extensive review. Life. 2025, 15(4): 582. (Open Access)
For research use only. Not intended for any clinical use.
